Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Shares of CARA stock opened at $5.70 on Friday. The company has a market capitalization of $26.07 million, a price-to-earnings ratio of -0.27 and a beta of 0.50. Cara Therapeutics has a one year low of $2.71 and a one year high of $11.52. The company’s 50-day moving average is $4.99 and its 200 day moving average is $4.18.

Hedge Funds Weigh In On Cara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CARA. XTX Topco Ltd purchased a new stake in Cara Therapeutics during the 3rd quarter valued at $29,000. FMR LLC lifted its holdings in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares in the last quarter. Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics during the fourth quarter valued at $277,000. Shay Capital LLC bought a new stake in Cara Therapeutics in the 4th quarter worth about $524,000. Finally, Rockefeller Capital Management L.P. purchased a new position in Cara Therapeutics in the 4th quarter worth about $953,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.